A Transcriptomic Biomarker for Predicting the Response to TACE Correlates with the Tumor Microenvironment and Radiomics Features in Hepatocellular Carcinoma
Open Access
- 1 November 2024
- journal article
- research article
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 11, 2321-2337
Abstract
Purpose: The response to transarterial chemoembolization (TACE) varies among individuals with hepatocellular carcinoma (HCC). This study aimed to identify a biomarker for predicting TACE response in HCC patients and to investigate its correlations with the tumor microenvironment and pre-TACE radiomics features. Patients and Methods: GSE104580 data were obtained from the Gene Expression Omnibus (GEO) database. Differentially expressed gene analysis and machine learning algorithms were used to identify genes for constructing the TACE failure signature (TFS). TFS scores were then calculated for HCC patients in The Cancer Genome Atlas (TCGA) cohort. After obtaining images from The Cancer Imaging Archive (TCIA), tumor labeling and radiomics feature extraction, the Rad-score model was generated. Correlation analysis was performed between the TFS score and the Rad-score. CIBERSORT, ssGSEA and TME analysis were performed to explore differences in the immune landscape among distinct risk groups. The immunotherapy response was compared between different groups. Results: ADH1C, CXCL11, EMCN, SPARCL1 and LIN28B were selected and incorporated into the TFS, which demonstrated satisfactory performance in predicting TACE response. Patients in the high TFS score group had poorer overall survival (OS) than those in the low TFS score group. The Rad-score model was constructed using six radiomics features, and the Rad-score was significantly correlated with hub gene expression and the TFS score. The high-TFS group was also characterized by an immunosuppressive tumor microenvironment and exhibited unfavorable responses to immunotherapy with PD-1 and CTLA-4 checkpoint inhibitors. Conclusion: This study established a transcriptomic biomarker for predicting the efficacy of TACE that correlates with radiomics features on pretreatment imaging, tumor immune microenvironment characteristics, and the efficacy of immunotherapy and targeted therapy in HCC patients.Keywords
This publication has 51 references indexed in Scilit:
- The Immune Landscape of CancerImmunity, 2018
- CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation – A target for novel cancer therapyCancer Treatment Reviews, 2018
- Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinomaGut, 2015
- STARD 2015: an updated list of essential items for reporting diagnostic accuracy studiesBMJ, 2015
- Transarterial Chemoembolization Failure/Refractoriness: JSH-LCSGJ Criteria 2014 UpdateOncology, 2014
- Traditional herbal medicine in preventing recurrence after resection of small hepatocellular carcinoma: a multicenter randomized controlled trialJournal of Integrative Medicine, 2013
- TIE2-expressing monocytes as a diagnostic marker for hepatocellular carcinoma correlates with angiogenesisHepatology, 2012
- Human carbonyl reductase 1 upregulated by hypoxia renders resistance to apoptosis in hepatocellular carcinoma cellsJournal of Hepatology, 2011
- SPARC and Hevin expression correlate with tumour angiogenesis in hepatocellular carcinomaThe Journal of Pathology, 2006
- Identification of human endomucin‐1 and ‐2 as membrane‐bound O‐sialoglycoproteins with anti‐adhesive activity1FEBS Letters, 2001